IL2RG antibody (APC)

Catalog No. ABIN2658475

Product Details anti-IL2RG Antibody (APC)

Target: IL2RG (Interleukin 2 Receptor, gamma (IL2RG))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This IL2RG antibody is conjugated to APC

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

Clone: TUGm2

Isotype: IgG2b kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for IL2RG

Target: IL2RG (Interleukin 2 Receptor, gamma (IL2RG))

Alternative Name: CD132 (IL2RG Products)

Synonyms: Ab2-183 antibody, Cd132 antibody, CD132 antibody, CIDX antibody, IL-2RG antibody, IMD4 antibody, P64 antibody, SCIDX antibody, SCIDX1 antibody, [g]c antibody, gamma(c) antibody, gc antibody, interleukin 2 receptor subunit gamma antibody, interleukin 2 receptor subunit gamma L homeolog antibody, interleukin 2 receptor, gamma chain antibody, IL2RG antibody, il2rg.L antibody, Il2rg antibody

Background: CD132 is a 64-70 kD type I transmembrane glycoprotein of the Ig superfamily, and is also known as common γ chain (γc) or IL-2 receptor γ subunit. It is expressed broadly on T- and B-lymphocytes, NK cells, monocytes, and granulocytes. CD132 is an essential component of cytokine receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Ligand binding induces tyrosine phosphorylation and initiates signaling through a JAK/STAT pathway. CD132 mutation results in X-linked severe combined immune deficiency (XSCID).

Pathways: JAK-STAT Signaling, Growth Factor Binding